<DOC>
	<DOCNO>NCT01092754</DOCNO>
	<brief_summary>The objective study characterize safety , efficacy pharmacokinetic profile Optimark standard clinical dose 0.1 mmol/kg pediatric patient population .</brief_summary>
	<brief_title>Study Evaluate Safety , Efficacy Pharmacokinetics Optimark ( Gadoversetamide ) Pediatric Patients</brief_title>
	<detailed_description>Pediatric patient refer magnetic resonance imaging ( MRI ) liver central nervous system ( CNS ) stratify age one two group ( 2 11 12 18 year age ) .</detailed_description>
	<mesh_term>Pathologic Processes</mesh_term>
	<criteria>2 thru 18 year age refer MRI liver CNS female childbearing potential , must negative pregnancy test within 24 hour study drug administration applicable , agree use medically accept method contraception throughout study necessary , patient enter PK subgroup must willing house within investigational facility minimum 24 hour follow drug administration understand requirement study provide write consent participate , agree abide study requirement previously enter study previous study use Optimark receive investigational drug within 30 day admission study plan participate clinical study prior end study 's monitoring period . ( patient research protocol use approve drug ar acceptable ) medical condition , serious intercurrent illness , extenuate circumstance would significantly decrease study compliance prescribe follow know suspect abnormal renal function age require dialysis study period pregnant breastfeeding schedule undergo contrastenhanced examination within 7 day prior baseline examination course study period condition contraindication MRI ( i.e. , cardiac pacemaker , epicardial pacemaker lead , cochlear implant , ferromagnetic aneurysm clip , ferromagnetic halo device , condition would preclude patient proximity strong external magnetic field ) experience previous hypersensitivity reaction gadoliniumbased contrast agent recent history hemolytic anemia , sickle cell anemia , hemoglobinopathy undergone surgical procedure within one week prior study admission plan undergo surgical procedure study participation ( central line placement acceptable ) history significant claustrophobia weigh less 25 lb ( 11 kg )</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>brain , spine , liver , MRI , Pediatric</keyword>
</DOC>